The Focused Ultrasound Foundation and the Children’s Tumor Foundation (CTF) have established a partnership to advance revolutionary, noninvasive therapies in pediatrics. For greater than 15 years, the Focused Ultrasound Foundation has been devoted to advancing the event and adoption of centered ultrasound. Likewise, for over 40 years, CTF has been a pacesetter in driving analysis, increasing information, and advancing take care of the neurofibromatosis group.
To launch the partnership, the 2 organizations are co-funding an early-stage laboratory examine to analyze centered ultrasound’s function in addressing neurofibromatosis sort 2, or NF2 (now often called NF2-related schwannomatosis). NF2 is a uncommon genetic situation that causes tumors to develop alongside the nerves. While the tumors are benign, they’ll result in severe well being situations, together with listening to loss, tinnitus, hydrocephalus, and compression of the brainstem.
“Treatment options for NF2 patients are limited to high-risk surgery, chemotherapy, or radiation therapy, which carry high risks of morbidity. The development of more nonsurgical treatments, like focused ultrasound, offer much promise in more effectively and safely helping patients,” mentioned Tracy Galloway, Children’s Tumor Foundation Board of Directors Chair. “On a personal level, it’s devastating to see what NF2-related tumors can do to a person, like my daughter, who just underwent her third brain surgery, this time to remove a vestibular schwannoma located at the juncture where the hearing, balance, and facial nerves come together. Her recovery is ongoing, but she lost her hearing and other side effects, and it would be our greatest hope to not have to subject patients to severe surgeries and their devastating after effects. Though this journey has been tough for us personally, we know new options are on the horizon and we are proud to partner with the Focused Ultrasound Foundation and Dr. Tyrone Porter in order to help as many patients as quickly as possible. We believe this could be a real game-changer in improving the quality of life of those living with NF2.”
Tyrone Porter, PhD, the Donald J. Douglass Centennial Professor in Engineering and an skilled in image-guided drug supply within the Department of Biomedical Engineering on the University of Texas at Austin, is the principal investigator for the examine. He and his staff will use centered ultrasound to ship a drug generally used for lung most cancers to a preclinical mannequin of NF2. The drug shall be wrapped in a particular thermosensitive liposome packaging, and researchers hope to find out whether or not this packaging will reduce the drug’s systemic unwanted effects. If that is the case, it might be potential to extend the native focus of the drug and thus improve its effectiveness. This liposome encapsulation method has helped with drug supply to different varieties of mind tumors, together with glioblastoma.
Dr. Porter is worked up to accomplice with CTF and the Focused Ultrasound Foundation to develop a brand new therapy possibility for NF2.
Thermosensitive liposomes have confirmed to be an efficient device for localized supply of anticancer brokers to strong tumors, predominantly in grownup sufferers. Focused ultrasound permits for triggered drug launch particularly within the tumor, thus minimizing systemic publicity and the related poisonous results. We imagine this therapy technique may be equally efficient towards pediatric mind tumors.”
Dr. Tyrone Porter, PhD, the Donald J. Douglass Centennial Professor in Engineering
“This study is a first step toward addressing some of the unmet needs in the pediatric field,” mentioned Focused Ultrasound Foundation Chairman Neal F. Kassell, MD. “The Foundation recognizes the tremendous impact that focused ultrasound could have on young patients because it avoids surgery and radiation therapy and has fewer side effects than more traditional treatments. We are honored to partner with CTF and Dr. Porter on this project.”
In August 2020, the Focused Ultrasound Foundation and CTF first collaborated to host a webinar and digital panel dialogue that launched centered ultrasound to the neurofibromatosis (NF) analysis group.
Posted in: Child Health News | Medical Research News | Medical Condition News
Tags: Alzheimer’s Disease, Blindness, Bone, Brain, Brain Surgery, Cancer, Chemotherapy, Children, Deafness, Drug Delivery, Essential Tremor, Galloway, Genetic, Glioblastoma, Hearing, Hearing Loss, Hydrocephalus, Imaging, Laboratory, Liposome, Liposomes, Liver, Lung Cancer, Neurofibromatosis, Pain, Pancreas, Parkinson’s Disease, Pediatrics, Preclinical, Prostate, Radiation Therapy, Research, Surgery, Tinnitus, Tremor, Tumor, Ultrasound, Uterine Fibroids, Vestibular Schwannoma, Webinar
If you are interested in working in a distraction free environment, visit our site Blissful Noises where we provide various sounds and features to help you focus or relax.